Decibel Therapeutics Inc., a Boston-based organization dedicated to treating hearing and balance disorders, is on the verge of another gene therapy breakthrough. The company develops novel treatments for curing hearing loss. Decibel Therapeutics recently secured $820 million for its new investigational approach for correcting permanent deafness.
The company’s R&D methodology has seen transformations in 2020. The company presented the idea of using gene replacement as the restorative therapy for hearing loss. The theory states the cause of congenital deafness in children is due to the mutation of the otoferlin gene. Replacing the faulty genes can resolve the condition. Interestingly, a lot is going on in terms of restoring hearing loss.
READ MORE: Person-First ‘…